Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
oncgnostics GmbH
About
Oncgnostics develops IVD tests for screening, therapeutic decision making, and follow-up care in cancer diagnostics.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Diagnostics,Medical,Robotics
- Founded date
- Feb 1, 2012
- Number Of Employee
- 1 - 10
- Operating Status
- Active
oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable in vitro diagnostic (=IVD) tests for screening, therapeutic decisions and follow-up care in cancer diagnostics.The diagnostic tests developed by oncgnostics are based on DNA regions specifically methylated in precancerous and carcinoma cells. These marker regions are detected using well-established PCR-based technologies, which can be performed in routine molecular diagnostics laboratories with standard equipment. oncgnostics has identified novel markers for detecting cervical precancerous lesions and carcinomas.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 29, 2015 | Series A | — | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Sparkasse Jena
|
— | Series A |
